comprehensive -WSS

comprehensive

author：leisure time 2025-09-30 17:43:44 - browse：752

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

The Danish pharmaceutical company Novo Nordisk has shepherded all kinds of medical innovation in the 110 years since it was founded. But the booming success of its diabetes and obesity drug is unlike anything executives have seen before.

The company’s mid-year operating profit jumped from 37.5 billion Danish kroner in 2022 to 48.9 billion Danish kroner this year — “probably the strongest growth in the history of the company,” Chief Financial Officer Karsten Munk Knudsen said during an August earnings call. The 30% growth rate came from sales of semaglutide, which Novo Nordisk sells for diabetes under the name Ozempic and for obesity as Wegovy.

With its new blockbuster drug in hand, Novo Nordisk is valued higher than the entire economy of Denmark, where it’s based.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Covid vaccine financial winners and losers, from Pfizer to Novavax

WSS

Study says nonprofit hospitals fall short in charity care spending

Physicians aren't 'burning out.' They're suffering from moral injury

Eliminate the waiting period for sterilization covered by Medicaid

Late stage cancers on the rise after pandemic delayed screenings

'Null' research findings aren't empty of meaning. Let's publish them

Medicare slashes safety net hospital payments by nearly $1 billion

hotspot

comprehensive

entertainment

Cancer drug shortages should be causing more outrage

Flint parents haunted by uncertainty, fears of lead poisoning

Virginia high school admissions case could be legal follow

Food as medicine: Medically tailored meals may get standardized

After affirmative action ruling, medical educators look to 'holistic review'

Alnylam reports growth in sales of rare disease treatments

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Eliminate the waiting period for sterilization covered by Medicaid

Novavax promises a turnaround & Lilly roils the obesity market

How I helped Pfizer think through the ethics of Viagra

focus

The a glaring gap in research on serious mental illness and primary care

Abortion pill case raises question: who can sue the FDA?

Oprah kicked off a national conversation on obesity. Let's have it

Washington mulls new rules to avert another Change Healthcare

Group behind ProMed defends move to subscription

FDA scientists endorse Pfizer/BioNTech Covid

focus

explore

focus

explore